Validation of psoriasis severity classification based on use of topical or systemic treatment.

In recent years, population-based studies have reported a considerable burden of disease among patients with psoriasis. Cumulative epidemiological data suggests that patients with psoriasis have an increased incidence and prevalence of cardio-metabolic comorbidities and a disease-severity dependent relationship is often reported. An accepted classification system is the Psoriasis Area and Severity Index (PASI), where one proposed categorization suggests that a score of less than 7 as mild, a score between 7 and 12 is moderate, and a score greater than 12 is consistent with severe psoriasis. This article is protected by copyright. All rights reserved.